EasySep™ Human Monocyte Enrichment Kit without CD16 Depletion
Immunomagnetic negative selection of untouched human memory CD8+ T cells
Easily and efficiently isolate highly purified human memory CD8+ T cells (CD8+CD45RA-CD45RO+) from fresh or previously frozen human peripheral blood mononuclear cells (PBMCs) or lysed leukapheresis samples by immunomagnetic negative selection, with the EasySep™ Human Memory CD8+ T Cell Enrichment Kit. Widely used in published research for more than 20 years, EasySep™ combines the specificity of monoclonal antibodies with the simplicity of a column-free magnetic system.
In this EasySep™ negative selection procedure, unwanted cells are labeled with antibody complexes and magnetic particles. Unwanted cells expressing the following markers are targeted for removal: CD4, CD14, CD16, CD19, CD20, CD34, CD36, CD45RA, CD56, CD61, CD66b, CD123, TCRγ/δ, and gly A. The magnetically labeled cells are then separated from the untouched desired memory CD8+ T cells by using an EasySep™ magnet and simply pouring the desired cells into a new tube. Following magnetic cell isolation, the desired memory CD8+ T cells are ready for downstream applications such as flow cytometry, culture, or cell-based assays.
Learn more about how immunomagnetic EasySep™ technology works or how to fully automate immunomagnetic cell isolation with RoboSep™. Alternatively, choose ready-to-use, ethically sourced, primary Human Peripheral Blood CD8+ Memory T Cells, Frozen isolated with EasySep™ Human Memory CD8+ T Cell Enrichment Kit. Explore additional products optimized for your workflow, including culture media, supplements, antibodies, and more.
In this EasySep™ negative selection procedure, unwanted cells are labeled with antibody complexes and magnetic particles. Unwanted cells expressing the following markers are targeted for removal: CD4, CD14, CD16, CD19, CD20, CD34, CD36, CD45RA, CD56, CD61, CD66b, CD123, TCRγ/δ, and gly A. The magnetically labeled cells are then separated from the untouched desired memory CD8+ T cells by using an EasySep™ magnet and simply pouring the desired cells into a new tube. Following magnetic cell isolation, the desired memory CD8+ T cells are ready for downstream applications such as flow cytometry, culture, or cell-based assays.
Learn more about how immunomagnetic EasySep™ technology works or how to fully automate immunomagnetic cell isolation with RoboSep™. Alternatively, choose ready-to-use, ethically sourced, primary Human Peripheral Blood CD8+ Memory T Cells, Frozen isolated with EasySep™ Human Memory CD8+ T Cell Enrichment Kit. Explore additional products optimized for your workflow, including culture media, supplements, antibodies, and more.
Data Figures
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Resources and Publications
Educational Materials (7)
Frequently Asked Questions
Publications (1)
Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression. Nature communications 2018 OCT
Abstract
Functional CD8+ T cells in human tumors play a clear role in clinical prognosis and response to immunotherapeutic interventions. PD-1 expression in T cells involved in chronic infections and tumors such as melanoma often correlates with a state of T-cell exhaustion. Here we interrogate CD8+ tumor-infiltrating lymphocytes (TILs) from human breast and melanoma tumors to explore their functional state. Despite expression of exhaustion hallmarks, such as PD-1 expression, human breast tumor CD8+ TILs retain robust capacity for production of effector cytokines and degranulation capacity. In contrast, melanoma CD8+ TILs display dramatic reduction of cytokine production and degranulation capacity. We show that CD8+ TILs from human breast tumors can potently kill cancer cells via bi-specific antibodies. Our data demonstrate that CD8+ TILs in human breast tumors retain polyfunctionality, despite PD-1 expression, and suggest that they may be harnessed for effective immunotherapies.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
